Last reviewed · How we verify
NCT03430414
Analysis of Biopsies With Antibody Mediated Rejection According to the Therapy Response
trial testing Transcriptome Analysis in Antibody-mediated Rejection in 50 participants. Status unknown.
1 March 2018
Quick facts
| Lead sponsor | Thomas Mueller |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 15 February 2018 |
| Primary completion | 1 March 2018 |
| Estimated completion | 30 April 2018 |
Drugs / interventions tested
- Transcriptome Analysis
Conditions studied
- Antibody-mediated Rejection — all drugs for Antibody-mediated Rejection →
Sponsor
Thomas Mueller
Who can join
18 and older, any sex, with Antibody-mediated Rejection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In adult kidney transplant recipients a therapy-responder and non-responder phenotype by antibody mediated rejection will be precisely defined according to clinical and histological characteristics such as creatinine, proteinuria and Banff-classification. Twenty-five patients will be selected each in the therapy-responder and non-responder group. Their stored Formalin Fixed Paraffin Embedded (FFPE) biopsies will be (re)-classified according to the most recent Banff classification. Using Nanostring Technology the gene transcription of therapy-responders versus non-responders will be analyzed and compared to serological and clinical parameters.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Histologic and Molecular Patterns in Responders and Non-responders With Chronic-Active Antibody-Mediated Rejection in Kidney Transplants.
Sazpinar O, Gaspert A, Sidler D, Rechsteiner M, et al · · 2022 · PMID 35573002 · DOI 10.3389/fmed.2022.820085
Verify or expand the search:
- PubMed search for NCT03430414
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Antibody-mediated Rejection
Currently open trials in the same condition.
- NCT06685757 — A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have A · Phase 3 · recruiting
- NCT06112951 — A Prospective Randomized Trial of ECP in Subclinical AMR · NA · recruiting
- NCT05004493 — Biorepository and Registry for Plasma Exchange Patients · recruiting
- NCT05184426 — MuLtimodality EvaluatiOn of aNtibody mEdiated Damage in Heart Transplantation (LEONE-HT) · active not recruiting
- NCT03380962 — Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant · Phase 1, PHASE2 · active not recruiting
Other Thomas Mueller trials
Trials by the same sponsor.
- NCT03442647 — Dynamic Measurement of Renal Functional Reserve as a Predictor of Long-Term Renal Function · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03430414 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Thomas Mueller
- Last refreshed: 12 February 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03430414.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing